Neuronetics: Top Line Growth, Low Valuation, But Gross Margin Struggles
Neuronetics is revisited following prior coverage in March 2026. The article focuses on STIM's recent developments and their impact on the investment thesis. Key topics include operational progress, financial performance, and forward outlook for STIM.
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.21 per share a year ago.
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.29 per share a year ago.
Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Keith J. Sullivan - President, CEO & Director Steven E.
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.33 per share a year ago.
Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor Andrew - William Blair William Plovanic - Canaccord Genuity Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2025 Financial and Operating Results Conference Call.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.27 per share a year ago.
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025.
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet
The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Max Kruszeski - William Blair Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics Fourth Quarter 2024 Financial and Operating Results Conference Call.
